Mainz Biomed B.V. (MYNZ) | Investment Case

1. Company Snapshot

1.a. Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics.It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests.The company was founded in 2008 and is based in Mainz, Germany.

Show Full description

1.b. Last Insights on MYNZ

Mainz Biomed's recent performance faces challenges due to the inherent uncertainty and patience required in the small-cap biotech sector. Although the company announced positive topline results from its feasibility study on a non-invasive blood-based screening test for pancreatic cancer, there is no recent earnings release to provide clear financial guidance. Additionally, while Mainz Biomed has been engaging in various partnerships and showcasing its innovative cancer detection solutions, such as the agreement with OncoVanguard8 to bring ColoAlert to South America, these developments may not provide immediate financial returns. According to a recent note, speculative investors are advised to exercise patience.

1.c. Company Highlights

Last Price	0.68
Change Percentage	-11.30%
Open	0.74
Previous Close	0.77
Market Cap ( Millions)	3
Volume	32782
Year High	5.62
Year Low	0.55
M A 50	1.03
M A 200	1.46

FCF Yield	-560.41%
Dividend Yield	0.00%
ROE	-442.79%
Debt / Equity	122.65%
Net Debt / EBIDTA	-6.63%
Price To Book	0.85
Price Earnings Ratio	-0.11
Price To FCF	-0.18
Price To sales	4.22
EV / EBITDA	-0.22

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Mainz Biomed NV (NASDAQ:MYNZ) Short Interest Update

Feb -01

Source: defenseworld.net

Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

Jan -14

Source: globenewswire.com

2 Small-Cap Biotechs That Could Reward Patient Investors

Dec -12

Source: marketbeat.com

Mainz Biomed (NASDAQ:MYNZ) Shares Down 5.8% – What’s Next?

Nov -22

Source: defenseworld.net

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

Nov -18

Source: globenewswire.com

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Nov -12

Source: globenewswire.com

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Nov -10

Source: globenewswire.com

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Oct -08

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.27%)

6. Segments

Genetic Diagnostic Testing

Expected Growth: 10.27%

Mainz Biomed B.V.'s 10.27% growth in Genetic Diagnostic Testing is driven by increasing demand for non-invasive cancer diagnostics, advancements in genetic sequencing technologies, and growing adoption in emerging markets. Additionally, rising incidence of cancer and genetic disorders, coupled with government initiatives to promote early disease detection, are fueling growth in this segment.

7. Detailed Products

Colorectal Cancer Screening Test

A non-invasive, stool-based DNA test for the early detection of colorectal cancer

Colorectal Cancer Recurrence Test

A blood-based test for the detection of circulating tumor DNA in patients with a history of colorectal cancer

CRC-Protect

A blood-based test for the detection of methylated Septin 9, a biomarker for colorectal cancer

8. Mainz Biomed B.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Mainz Biomed B.V. is medium due to the availability of alternative diagnostic tests and treatments for cancer.

Bargaining Power Of Customers

The bargaining power of customers for Mainz Biomed B.V. is low due to the specialized nature of the company's products and services.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Mainz Biomed B.V. is medium due to the availability of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

The threat of new entrants for Mainz Biomed B.V. is high due to the growing demand for cancer diagnostics and the potential for new companies to enter the market.

Intensity Of Rivalry

The intensity of rivalry for Mainz Biomed B.V. is high due to the competitive nature of the cancer diagnostics market and the presence of established companies.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	69.55%
Debt Cost	5.35%
Equity Weight	30.45%
Equity Cost	5.35%
WACC	5.35%
Leverage	228.39%

11. Quality Control: Mainz Biomed B.V. passed 1 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Lumibird

A-Score: 3.8/10

Value: 2.5

Growth: 5.4

Quality: 3.5

Yield: 0.0

Momentum: 10.0

Volatility: 1.3

1-Year Total Return ->

Centogene

A-Score: 3.5/10

Value: 10.0

Growth: 1.6

Quality: 5.5

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

Moolec Science

A-Score: 3.1/10

Value: 7.8

Growth: 3.3

Quality: 2.5

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

Vimian Group

A-Score: 3.1/10

Value: 1.9

Growth: 7.2

Quality: 6.2

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

Selvita

A-Score: 2.8/10

Value: 5.0

Growth: 4.9

Quality: 3.9

Yield: 0.0

Momentum: 1.0

Volatility: 2.0

1-Year Total Return ->

Mainz Biomed

A-Score: 2.6/10

Value: 8.2

Growth: 3.3

Quality: 4.2

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

11.80%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

5.35%

Mainz Biomed B.V. - NL0015000LC2

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on MYNZ

1.c. Company Highlights

Weak Momentum

Lower Growth

More Volatile

Earnings Beats

Earnings Miss

Revenues Miss

Strong Momentum

Cheaper

Revenues Beats

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.27%)

6. Segments

Genetic Diagnostic Testing

Expected Growth: 10.27%

7. Detailed Products

Colorectal Cancer Screening Test

Colorectal Cancer Recurrence Test

CRC-Protect

8. Mainz Biomed B.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Mainz Biomed B.V. passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.68$

Current Price

0.68$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA